Testosterone for women has gone from something almost nobody discussed to something almost everybody has an opinion about. Podcasts describe it as the missing piece. Private clinics advertise it for energy, focus, muscle and motivation. Women arrive at appointments having already decided they want it.
The prescribing numbers tell the same story. In England, the number of women aged 50 and over receiving testosterone gel rose from 429 in November 2015 to 4,675 in November 2022. Roughly ten times more, in seven years.
Underneath the enthusiasm sits a body of evidence that is genuinely good, but far narrower than the conversation around it. Knowing where that line falls is the difference between a treatment that helps you and an expensive disappointment.
Women produce testosterone in the ovaries and adrenal glands, in smaller amounts than men but not trivial ones. It contributes to sexual desire, and it plays a part in muscle and bone.
Levels fall gradually with age rather than dropping at menopause the way oestrogen does. By your forties you are producing roughly half what you did in your twenties, and that decline began long before your cycle changed. There is no sudden testosterone cliff to match the oestrogen one, which is part of why symptoms are hard to pin on it.
Our guide to oestrogen, progesterone and testosterone covers what each one does across your life.
In 2019, ten international medical societies published a joint position statement on testosterone therapy for women. It remains the most authoritative document on the subject, and it is unusually direct.
Its conclusion, in the panel's own framing: the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder, with the available data supporting a moderate therapeutic effect. There are insufficient data to support its use for any other symptom, condition, or for preventing disease.
That word moderate is doing honest work. Trials show a real improvement in desire and in the number of satisfying sexual events, but it is a meaningful shift rather than a transformation.
The condition it treats is also narrower than "low libido." Hypoactive sexual desire disorder means persistently absent or reduced desire that causes you personal distress, and that is not better explained by a medication, a relationship difficulty, depression, or another medical condition. A woman whose desire has dropped and who is not troubled by it does not have HSDD. Neither does a woman whose desire dropped three months after starting an antidepressant.
This is where the gap between evidence and marketing is widest, and where most women's expectations are set.
The same consensus statement addressed these directly.
Read that list against what testosterone is currently sold for and the mismatch is obvious. The clinic promising energy and focus is promising something the evidence does not deliver.
If your problem is fatigue, brain fog, or lost muscle, there are explanations with far better evidence behind them. Brain fog is usually driven by disrupted sleep and fluctuating oestrogen, and it lifts. Muscle loss responds to resistance training in a way no hormone matches. Persistent exhaustion warrants checking thyroid function and iron before anything else.
No regulator in the UK, the US, or most of the world has approved a testosterone product for women. Every prescription is off-label, meaning a licensed medicine is being used outside its approved indication.
Off-label is not the same as unregulated or improper. Doctors prescribe off-label routinely and legally, and it is supported here by consensus guidelines from the relevant specialist societies. But it has three practical consequences worth knowing.
Products are made for men. A woman needs roughly a tenth of a male dose, so she is measuring out a fraction of a sachet or a few clicks of a pump designed for someone needing ten times as much. Getting that consistently right is harder than it should be.
Availability is patchy. Some products have been intermittently unavailable, and access varies by region and by prescriber willingness.
Not every clinician will prescribe it. Some are uncomfortable prescribing off-label, and that is a defensible position rather than obstruction.
NICE guidance is specific about sequence: a trial of conventional HRT comes first, and testosterone is considered afterwards for women whose low desire persists despite it.
That order is not bureaucratic. Oestrogen deficiency causes vaginal dryness and discomfort, and pain during sex suppresses desire on its own. Treat the pain and desire often returns without any testosterone at all. Vaginal dryness and intimacy covers the options, several of which are simple and effective.
The consensus statement also restricts its recommendation to postmenopausal women. For women still cycling, the evidence is thinner, though some data support use in late reproductive age.
Before testosterone is a reasonable question, the things that suppress desire more commonly should have been excluded.
Where did my libido go? works through the full picture.
There is no testosterone level that diagnoses HSDD, and no threshold below which a woman is deemed deficient. The condition is diagnosed from symptoms and distress, not from a number.
Testing does have a role, but a specific one: measuring a baseline before starting, and checking afterwards that levels have not risen above the normal female range.
The consensus panel added a point that cuts against common practice. Research and clinical monitoring should focus on total testosterone, because the evidence that free testosterone represents the biologically active fraction in women is lacking. Many private panels emphasise free testosterone. That emphasis is not well supported here.
Should you get your hormones tested? covers when testing earns its place more generally.
The safety evidence applies to transdermal testosterone at doses producing normal female blood levels. Gels and creams applied to the skin.
The consensus statement explicitly excludes injections, implanted pellets, and compounded preparations from its recommendations, along with anything producing levels above the physiological female range. Those routes have not been shown to be safe in women, and they are harder to reverse: a pellet cannot be removed once the dose proves too high.
This matters because private clinics do offer pellets and injections, sometimes presented as more convenient. Convenience is not the trade being made.
At correct doses, meta-analysis found no serious adverse events. That is genuinely reassuring, and it comes with two caveats: long-term safety has not been established, and the reassurance applies only to physiological dosing.
Effects to watch for, most of which signal the dose is too high:
Sensible monitoring means a baseline level, a repeat at three to six months, and periodic checks afterwards, alongside a review of whether it is actually helping. If desire has not improved after six months, continuing is not the answer.
Pregnancy and breastfeeding. Active hormone-sensitive cancer, without specialist input. Untreated significant hair loss or hirsutism, where testosterone will worsen it. And any woman whose low desire has an identified cause that has not yet been addressed.
If you have read this far and still think testosterone might be right for you, the conversation goes better when it is specific.
Say what is happening and that it distresses you, rather than asking for a product by name. Confirm you have tried conventional HRT, or explain why it is not suitable. Ask directly whether your prescriber is willing to prescribe off-label, because some are not and finding out early saves months. Ask for transdermal, and ask what dose and what monitoring.
And ask the question most likely to be skipped: what should I expect this to change, and by when? A good answer names desire specifically, describes a moderate improvement, and sets a review point. An answer that promises energy, focus and body composition is a warning sign about the clinic rather than a promise about the treatment.
Our full guide to HRT covers the wider decision, and the free hormone quiz can help you organise your symptoms before an appointment.
Testosterone therapy for women is a real treatment with real evidence, for one problem. For postmenopausal women with persistent, distressing low desire that has not responded to conventional HRT, it offers a moderate and worthwhile improvement, and it appears safe at correct doses through the skin.
For everything else it is currently sold for, the evidence is either insufficient or, in the case of general wellbeing, actively negative.
That is not an argument against it. It is an argument for knowing which problem you are treating, so that you can tell whether it worked.
What does testosterone do for women?
It contributes to sexual desire and plays a part in muscle and bone. As a treatment, the only evidence-based use is for hypoactive sexual desire disorder in postmenopausal women.
Will testosterone give me more energy?
The evidence does not support it. The 2019 international consensus found no effect of testosterone on general wellbeing in postmenopausal women, and insufficient evidence for mood, energy or cognition.
Can I get testosterone on the NHS?
Yes, though it is prescribed off-label and availability varies. NICE guidance suggests trying conventional HRT first, with testosterone considered if low desire persists.
Is testosterone safe for women?
Meta-analysis found no serious adverse events with transdermal testosterone at doses keeping levels within the normal female range. Long-term safety has not been established, and the evidence does not extend to injections, pellets or compounded preparations.
Do I need a blood test first?
There is no level that diagnoses low testosterone in women, and diagnosis rests on symptoms. Testing is used for a baseline and to confirm levels stay within the female range afterwards.
How long before I know if it is working?
Allow three to six months. If desire has not improved by then, it is not going to, and continuing is not justified.
Will it help me build muscle?
There is insufficient evidence to support that use. Resistance training remains the intervention with the strongest evidence for preserving muscle in midlife.
Sources: Davis SR, Baber R, Panay N et al., Global consensus position statement on the use of testosterone therapy for women, J Clin Endocrinol Metab 2019;104(10):4660-6 · Islam RM, Bell RJ, Green S et al., Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data, Lancet Diabetes Endocrinol 2019;7(10):754-66 · Parish SJ, Simon JA, Davis SR et al., ISSWSH clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women, J Sex Med 2021;18(5):849-67 · Parish SJ, Kling JM, NAMS Practice Pearl: testosterone use for hypoactive sexual desire disorder in postmenopausal women, Menopause 2023;30(7):781-3 · NICE NG23, Menopause: identification and management · NHS prescribing data for testosterone in women aged 50 and over, England, 2015-2022 · Educational only, not medical advice. Testosterone therapy is a decision to make with a clinician who knows your history.
Keep reading: Where did my libido go? · Vaginal dryness and intimacy · The truth about HRT research · Medications that lower libido · Our full guide to HRT · Take the free Hormone Quiz